EichorEICHORAboutSolutions
Study identifier: NCT06828328 Synced from ClinicalTrials.gov · August 05, 2026
● Recruiting

A Study of GC203 TIL in PDCA (RJ)

Condition: Pancreatic Cancer · Pancratic Ductal Adenocarcinoma · Treatment Side Effects  ·  Sponsor: Shanghai Juncell Therapeutics

PhaseEARLY_Phase 1
Planned participants10
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

This study is to investigate the safety and efficacy of gene-edited tumor infiltrating lymphocyte (GC203 TIL) therapy in patients with pancreatic ductal adenocarcinoma. Gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

This description comes directly from the study's public registry record.

Talk to the study team

boyong shen  ·  086-18001759113  ·  clinicaltrials@juncell.com

Always discuss trial participation with your own doctor first.

Locations (1)

Ruijin HospitalShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06828328